GNPX - Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

An Institutional Review Board ("IRB") has granted approval for Genprex's (GNPX) phase 1/2 trial testing its REQORSA immunogene therapy with AstraZeneca’s Tagrisso (osimertinib) in late-stage non-small cell lung cancer.The Acclaim-1 trial will include about 92 patients: Up to 18 patients in phase 1 and 74 patients in phase 2.An interim analysis will be conducted after 25 clinical events.The patient population for the trial has Fast Track designation.Genprex shares are up 4.1% to $3.83 in premarket trading.

For further details see:

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%